The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Protein Toxin Chaperoned by LRP‐1‐Targeted Virus‐Mimicking Vesicles Induces High‐Efficiency Glioblastoma Therapy In Vivo
Abstract
Glioblastoma is a most intractable and high‐mortality malignancy because of its extremely low drug accessibility resulting from the blood–brain barrier (BBB). Here, it is reported that angiopep‐2‐directed and redox‐responsive virus‐mimicking polymersomes (ANG‐PS) (angiopep‐2 is a peptide targeting to low‐density lipoprotein receptor‐related protein‐1 (LRP‐1)) can efficiently and selectively chaperone saporin (SAP), a highly potent natural protein toxin, to orthotopic human glioblastoma xenografts in nude mice. Unlike chemotherapeutics, free SAP has a low cytotoxicity. SAP‐loaded ANG‐PS displays, however, a striking antitumor activity (half‐maximal inhibitory concentration, IC 50 = 30.2 × 10−9m) toward U‐87 MG human glioblastoma cells in vitro as well as high BBB transcytosis and glioblastoma accumulation in vivo. The systemic administration of SAP‐loaded ANG‐PS to U‐87 MG orthotopic human‐glioblastoma‐bearing mice brings about little side effects, effective tumor inhibition, and significantly improved survival rate. The protein toxins chaperoned by LRP‐1‐targeted virus‐mimicking vesicles emerge as a novel and highly promising treatment modality for glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of microglia and macrophages in glioma maintenance and progression
Hambardzumyan, D., Gutmann, D. H., & Kettenmann, H. (2016) · Nature Neuroscience · doi:10.1038/nn.4185 · Cited by 1,683
Establishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557
Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30313-8 · Cited by 495
Co-delivery of chemotherapeutics and proteins for synergistic therapy
He, C., Tang, Z., Tian, H., & Chen, X. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.021 · Cited by 231
Angiopep‐Conjugated Electro‐Responsive Hydrogel Nanoparticles: Therapeutic Potential for Epilepsy
Ying, X., Wang, Y., Liang, J., Yue, J., Xu, C., Lu, L., Xu, Z., Gao, J., Du, Y., & Chen, Z. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403846 · Cited by 143
Double function at the blood–brain barrier
Betsholtz, C. (2014) · Nature · doi:10.1038/nature13339 · Cited by 63
Cited by
Emerging blood–brain-barrier-crossing nanotechnology for brain cancer theranostics
Tang, W., Fan, W., Lau, J., Deng, L., Shen, Z., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00805a · Cited by 605
Overcoming blood–brain barrier transport: Advances in nanoparticle-based drug delivery strategies
Ding, S., Khan, A. I., Cai, X., Song, Y., Lyu, Z., Du, D., Dutta, P., & Lin, Y. (2020) · Materials Today · doi:10.1016/j.mattod.2020.02.001 · Cited by 440
Drug delivery to the central nervous system
Nance, E., Pun, S. H., Saigal, R., & Sellers, D. L. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00394-w · Cited by 414
Aliphatic Polycarbonates from Cyclic Carbonate Monomers and Their Application as Biomaterials
Yu, W., Maynard, E., Chiaradia, V., Arno, M. C., & Dove, A. P. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00883 · Cited by 355
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350
Metadata
- Authors
- Jiang, Y., Yang, W., Zhang, J., Meng, F., & Zhong, Z.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2018-06-11
- Volume
- 30
- Issue
- 30
- Pages
- e1800316-e1800316
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2808164384
- Cited by
- 164
- References
- 7
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.